Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats

被引:10
|
作者
Slovak, J. E. [1 ,2 ]
Rivera, S. M. [1 ,2 ]
Hwang, J. K. [1 ,2 ]
Court, M. H. [1 ,2 ]
Villarino, N. F. [1 ,2 ]
机构
[1] Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Program Individualized Med, Pullman, WA 99164 USA
[2] Washington State Univ, Pullman, WA 99164 USA
来源
JOURNAL OF VETERINARY INTERNAL MEDICINE | 2017年 / 31卷 / 06期
关键词
Cats; Immunosuppressant; Mycophenolate mofetil; Pharmacokinetics; HEART-FAILURE; DOGS; TORSEMIDE; FUROSEMIDE; TORASEMIDE;
D O I
10.1111/jvim.14827
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is becoming increasingly popular as an alternative immunosuppressant in feline medicine. Pharmacokinetic information is not available for cats. Objective: The purpose of this study was to determine whether MMF is biotransformed into the active metabolite MPA and to evaluate the disposition of MPA after a 2-hour constant rate intravenous (IV) infusion of MMF in healthy cats. Animals: Healthy cats (n = 6). Methods: This was a prospective pilot study. All cats were administered MMF at 20 mg/kg every 12 hours over a 2-hour constant rate infusion for 1 day. The concentrations of MPA and its derivatives in blood were determined using a validated UHPLC-UV method. Results: All cats biotransformed MMF into MPA. The mean AUC(0-14) (h) ranged from 6 to 50 h*mg/L after IV dosing of MMF. Transient large bowel diarrhea was recorded in 2 of 6 cats after medication administration. Conclusion and Clinical Importance: The disposition of MPA in plasma was highly variable, which could result in high interindividual variability in the safety and efficacy of treatment with MMF in cats.
引用
收藏
页码:1827 / 1832
页数:6
相关论文
共 50 条
  • [31] The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation
    Pieper, AK
    Buhle, F
    Bauer, S
    Mai, I
    Budde, K
    Haffner, D
    Neumayer, HH
    Querfeld, U
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (10) : 2630 - 2633
  • [32] Pharmacokinetics of Flunixin after Intravenous Administration in Healthy and Endotoxaemic Rabbits
    M. Elmas
    E. Yazar
    K. Uney
    A. Karabacak
    Veterinary Research Communications, 2006, 30 : 73 - 81
  • [33] Pharmacokinetics of flunixin after intravenous administration in healthy and endotoxaemic rabbits
    Elmas, M
    Yazar, E
    Uney, K
    Karabacak, A
    VETERINARY RESEARCH COMMUNICATIONS, 2006, 30 (01) : 73 - 81
  • [34] Pharmacokinetics of Protocatechuic Acid in Rats after Intravenous Administration
    Zhang, Dongchu
    Hu, Yujie
    Zhou, Caiping
    Feng, Tiantian
    Chen, Lianguo
    Ma, Jianshe
    LATIN AMERICAN JOURNAL OF PHARMACY, 2019, 38 (12): : 2401 - 2405
  • [35] Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
    Keiji Kurata
    Kimikazu Yakushijin
    Atsuo Okamura
    Motohiro Yamamori
    Hiroya Ichikawa
    Rina Sakai
    Yu Mizutani
    Seiji Kakiuchi
    Yoshiharu Miyata
    Akihito Kitao
    Shinichiro Kawamoto
    Hiroshi Matsuoka
    Tohru Murayama
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 839 - 846
  • [36] Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
    Kurata, Keiji
    Yakushijin, Kimikazu
    Okamura, Atsuo
    Yamamori, Motohiro
    Ichikawa, Hiroya
    Sakai, Rina
    Mizutani, Yu
    Kakiuchi, Seiji
    Miyata, Yoshiharu
    Kitao, Akihito
    Kawamoto, Shinichiro
    Matsuoka, Hiroshi
    Murayama, Tohru
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 839 - 846
  • [37] Evaluation of Pharmacokinetic Interactions After Oral Administration of Mycophenolate Mofetil and Valaciclovir or Aciclovir to Healthy Subjects
    François Gimenez
    Estelle Foeillet
    Olivier Bourdon
    Steve Weller
    Christophe Garret
    Roselyne Bidault
    Eric Singlas
    Clinical Pharmacokinetics, 2004, 43 : 685 - 692
  • [38] Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil
    Le Meur, Yannick
    Thierry, Antoine
    Glowacki, Francois
    Rerolle, Jean-Philippe
    Garrigue, Valerie
    Ouali, Nacera
    Heng, Anne-Elisabeth
    Delahousse, Michel
    Albano, Laeticia
    Lang, Philippe
    Couzi, Lionel
    Jaureguy, Maite
    Lebranchu, Yvon
    Mousson, Christiane
    Glotz, Denis
    Kessler, Michele
    Vrtovsnik, Francois
    Rouanet, Stephanie
    Tagieva, Nailya
    Kamar, Nassim
    TRANSPLANTATION, 2011, 92 (11) : 1244 - 1251
  • [39] Mycophenolic Acid Exposure in High- and Low-Weight Renal Transplant Patients After Dosing With Mycophenolate Mofetil in the Opticept Trial
    Kaplan, Bruce
    Gaston, Robert S.
    Meier-Kriesche, Herwig-Ulf
    Bloom, Roy D.
    Shaw, Leslie M.
    THERAPEUTIC DRUG MONITORING, 2010, 32 (02) : 224 - 227
  • [40] Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs
    Andaluz, Anna
    Moll, Xavier
    Abellan, Rosario
    Ventura, Rosa
    Carbo, Marcelli
    Fresno, Laura
    Garcia, Felix
    VETERINARY JOURNAL, 2009, 181 (03) : 299 - 304